| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 91 | 2025 | 168 | 12.570 |
Why?
|
| Carcinoma, Squamous Cell | 83 | 2025 | 254 | 9.530 |
Why?
|
| Laryngeal Neoplasms | 35 | 2024 | 51 | 4.500 |
Why?
|
| Oropharyngeal Neoplasms | 31 | 2024 | 38 | 3.710 |
Why?
|
| Mouth Neoplasms | 14 | 2025 | 34 | 2.770 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2022 | 344 | 2.700 |
Why?
|
| Papillomavirus Infections | 19 | 2024 | 127 | 2.470 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2022 | 40 | 1.870 |
Why?
|
| Laryngectomy | 19 | 2020 | 23 | 1.680 |
Why?
|
| Neoplasm Staging | 38 | 2024 | 500 | 1.590 |
Why?
|
| Biomarkers, Tumor | 15 | 2022 | 500 | 1.530 |
Why?
|
| Papillomaviridae | 18 | 2024 | 59 | 1.470 |
Why?
|
| Prognosis | 44 | 2022 | 1738 | 1.440 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 83 | 1.350 |
Why?
|
| Middle Aged | 109 | 2025 | 17489 | 1.230 |
Why?
|
| Disease-Free Survival | 25 | 2025 | 240 | 1.180 |
Why?
|
| Neck Dissection | 12 | 2024 | 18 | 1.120 |
Why?
|
| Survival Analysis | 25 | 2025 | 577 | 1.060 |
Why?
|
| Male | 118 | 2025 | 29707 | 1.040 |
Why?
|
| Cytokines | 6 | 2022 | 926 | 1.010 |
Why?
|
| Female | 116 | 2025 | 32654 | 0.980 |
Why?
|
| Neoplasm Invasiveness | 16 | 2023 | 276 | 0.980 |
Why?
|
| Humans | 168 | 2025 | 63003 | 0.970 |
Why?
|
| DNA Methylation | 6 | 2020 | 290 | 0.940 |
Why?
|
| Immunotherapy | 4 | 2021 | 254 | 0.930 |
Why?
|
| Aged | 77 | 2025 | 14335 | 0.910 |
Why?
|
| Salvage Therapy | 11 | 2020 | 74 | 0.880 |
Why?
|
| Survival Rate | 26 | 2020 | 845 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2022 | 446 | 0.810 |
Why?
|
| Chemoradiotherapy | 14 | 2024 | 66 | 0.790 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2018 | 19 | 0.740 |
Why?
|
| Antineoplastic Agents | 12 | 2022 | 662 | 0.700 |
Why?
|
| Isoflavones | 2 | 2019 | 16 | 0.690 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 670 | 0.670 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 2452 | 0.660 |
Why?
|
| Surgical Flaps | 4 | 2009 | 117 | 0.660 |
Why?
|
| Prospective Studies | 33 | 2025 | 3272 | 0.650 |
Why?
|
| Treatment Outcome | 40 | 2024 | 5630 | 0.630 |
Why?
|
| Cisplatin | 14 | 2022 | 139 | 0.620 |
Why?
|
| Adult | 57 | 2025 | 16723 | 0.620 |
Why?
|
| Retrospective Studies | 36 | 2024 | 6602 | 0.620 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2019 | 18 | 0.610 |
Why?
|
| Lymph Nodes | 7 | 2019 | 224 | 0.600 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2013 | 58 | 0.590 |
Why?
|
| Induction Chemotherapy | 8 | 2022 | 41 | 0.590 |
Why?
|
| Proportional Hazards Models | 17 | 2023 | 727 | 0.580 |
Why?
|
| Otorhinolaryngologic Neoplasms | 4 | 2010 | 5 | 0.560 |
Why?
|
| Diet | 6 | 2021 | 520 | 0.550 |
Why?
|
| Neoplasms, Squamous Cell | 3 | 2021 | 7 | 0.550 |
Why?
|
| Risk Assessment | 20 | 2019 | 2065 | 0.550 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2019 | 420 | 0.540 |
Why?
|
| Dietary Supplements | 1 | 2019 | 234 | 0.520 |
Why?
|
| Cohort Studies | 23 | 2022 | 2554 | 0.500 |
Why?
|
| Larynx | 5 | 2021 | 15 | 0.500 |
Why?
|
| Human papillomavirus 16 | 5 | 2020 | 17 | 0.500 |
Why?
|
| Genes, p53 | 3 | 2016 | 52 | 0.490 |
Why?
|
| Radiotherapy, Conformal | 3 | 2005 | 19 | 0.480 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2020 | 9 | 0.470 |
Why?
|
| Combined Modality Therapy | 17 | 2017 | 372 | 0.470 |
Why?
|
| Interleukin-6 | 7 | 2015 | 318 | 0.470 |
Why?
|
| Quality of Life | 14 | 2024 | 1223 | 0.460 |
Why?
|
| Aged, 80 and over | 27 | 2021 | 5432 | 0.460 |
Why?
|
| Histamine H2 Antagonists | 1 | 2014 | 15 | 0.460 |
Why?
|
| Tissue Array Analysis | 6 | 2020 | 37 | 0.450 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 42 | 0.450 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 92 | 0.430 |
Why?
|
| Mouth | 3 | 2021 | 35 | 0.410 |
Why?
|
| Smoking | 10 | 2025 | 864 | 0.410 |
Why?
|
| Deglutition Disorders | 5 | 2013 | 42 | 0.400 |
Why?
|
| Longitudinal Studies | 12 | 2025 | 1252 | 0.400 |
Why?
|
| Cell Line, Tumor | 12 | 2021 | 1458 | 0.390 |
Why?
|
| Papillomavirus E7 Proteins | 4 | 2020 | 7 | 0.380 |
Why?
|
| Parotid Gland | 2 | 2019 | 11 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2021 | 88 | 0.380 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 52 | 0.380 |
Why?
|
| ErbB Receptors | 4 | 2012 | 114 | 0.340 |
Why?
|
| Ethics, Medical | 1 | 2010 | 39 | 0.330 |
Why?
|
| Truth Disclosure | 1 | 2010 | 57 | 0.330 |
Why?
|
| Alphapapillomavirus | 2 | 2020 | 19 | 0.330 |
Why?
|
| Shoulder | 4 | 2021 | 28 | 0.310 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 203 | 0.310 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 86 | 0.310 |
Why?
|
| Viral Vaccines | 1 | 2009 | 47 | 0.310 |
Why?
|
| Adenoviridae | 1 | 2009 | 120 | 0.310 |
Why?
|
| Tracheostomy | 2 | 2020 | 36 | 0.300 |
Why?
|
| Deoxycytidine | 2 | 2014 | 41 | 0.290 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2008 | 3 | 0.290 |
Why?
|
| Paclitaxel | 5 | 2015 | 99 | 0.290 |
Why?
|
| Repressor Proteins | 3 | 2020 | 347 | 0.290 |
Why?
|
| Mutation | 5 | 2022 | 2597 | 0.290 |
Why?
|
| Bone Plates | 1 | 2008 | 37 | 0.290 |
Why?
|
| Patient Selection | 5 | 2017 | 488 | 0.280 |
Why?
|
| Michigan | 9 | 2021 | 43 | 0.270 |
Why?
|
| Antigens, CD | 2 | 2018 | 346 | 0.270 |
Why?
|
| Deglutition | 4 | 2020 | 18 | 0.270 |
Why?
|
| Lymph Node Excision | 3 | 2019 | 45 | 0.260 |
Why?
|
| Smoking Cessation | 3 | 2025 | 549 | 0.260 |
Why?
|
| Fluorouracil | 9 | 2022 | 65 | 0.260 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2016 | 35 | 0.260 |
Why?
|
| Indomethacin | 2 | 2020 | 22 | 0.260 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 79 | 0.250 |
Why?
|
| Probability | 4 | 2010 | 170 | 0.250 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 57 | 0.250 |
Why?
|
| Genomics | 1 | 2009 | 369 | 0.240 |
Why?
|
| Organ Preservation | 5 | 2024 | 19 | 0.230 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 636 | 0.230 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2015 | 6 | 0.230 |
Why?
|
| Nutritional Status | 3 | 2021 | 98 | 0.230 |
Why?
|
| Xerostomia | 2 | 2007 | 9 | 0.230 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2013 | 58 | 0.220 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2014 | 36 | 0.220 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 213 | 0.220 |
Why?
|
| Parotid Neoplasms | 2 | 2019 | 4 | 0.220 |
Why?
|
| Risk Factors | 15 | 2022 | 5324 | 0.210 |
Why?
|
| Radiation Injuries | 1 | 2004 | 66 | 0.210 |
Why?
|
| Tocopherols | 2 | 2020 | 10 | 0.210 |
Why?
|
| Salivary Glands | 1 | 2003 | 46 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2020 | 892 | 0.200 |
Why?
|
| Health Behavior | 4 | 2013 | 468 | 0.200 |
Why?
|
| Biopsy | 3 | 2018 | 441 | 0.200 |
Why?
|
| Otolaryngology | 1 | 2002 | 29 | 0.190 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 5 | 0.190 |
Why?
|
| Aspirin | 1 | 2023 | 171 | 0.190 |
Why?
|
| Genetic Therapy | 1 | 2009 | 784 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2002 | 14 | 0.190 |
Why?
|
| Tristetraprolin | 2 | 2013 | 7 | 0.190 |
Why?
|
| Postoperative Complications | 7 | 2017 | 1298 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.190 |
Why?
|
| Nutrition Disorders | 1 | 2021 | 7 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 38 | 0.180 |
Why?
|
| Microbiota | 1 | 2023 | 128 | 0.180 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 31 | 0.180 |
Why?
|
| Organ Sparing Treatments | 2 | 2024 | 16 | 0.180 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 198 | 0.180 |
Why?
|
| Cause of Death | 3 | 2017 | 220 | 0.180 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 279 | 0.180 |
Why?
|
| Cutaneous Fistula | 3 | 2017 | 7 | 0.180 |
Why?
|
| Pharyngeal Diseases | 3 | 2017 | 11 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 303 | 0.180 |
Why?
|
| Research | 1 | 2002 | 192 | 0.180 |
Why?
|
| Epithelium | 1 | 2021 | 95 | 0.180 |
Why?
|
| Carcinoma | 4 | 2014 | 122 | 0.180 |
Why?
|
| Intercellular Junctions | 1 | 2020 | 8 | 0.170 |
Why?
|
| Saliva | 2 | 2023 | 103 | 0.170 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 21 | 0.170 |
Why?
|
| Multivariate Analysis | 8 | 2018 | 932 | 0.170 |
Why?
|
| Omeprazole | 1 | 2020 | 5 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 324 | 0.170 |
Why?
|
| Anti-Ulcer Agents | 1 | 2020 | 9 | 0.170 |
Why?
|
| Virus Integration | 2 | 2017 | 32 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 14 | 0.170 |
Why?
|
| Keratinocytes | 1 | 2020 | 63 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 72 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 34 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 761 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 215 | 0.160 |
Why?
|
| Facial Nerve Injuries | 1 | 2019 | 4 | 0.160 |
Why?
|
| Vitamins | 2 | 2018 | 80 | 0.160 |
Why?
|
| Whole Grains | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mice | 11 | 2025 | 10751 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2017 | 60 | 0.160 |
Why?
|
| Employment | 2 | 2015 | 126 | 0.160 |
Why?
|
| Positron-Emission Tomography | 3 | 2017 | 204 | 0.160 |
Why?
|
| Zinc | 1 | 2020 | 91 | 0.160 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 45 | 0.160 |
Why?
|
| bcl-X Protein | 3 | 2009 | 20 | 0.160 |
Why?
|
| Electromyography | 1 | 2019 | 96 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2021 | 115 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2002 | 348 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2020 | 231 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 523 | 0.160 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 1080 | 0.160 |
Why?
|
| Animals | 15 | 2025 | 20501 | 0.160 |
Why?
|
| Remission Induction | 3 | 2009 | 148 | 0.160 |
Why?
|
| Neurons | 1 | 2025 | 918 | 0.160 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 99 | 0.150 |
Why?
|
| Carboplatin | 4 | 2015 | 43 | 0.150 |
Why?
|
| Peripheral Nerves | 2 | 2022 | 34 | 0.150 |
Why?
|
| Antigens, CD1 | 2 | 2015 | 41 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 99 | 0.150 |
Why?
|
| Proteolysis | 1 | 2020 | 145 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 2019 | 75 | 0.150 |
Why?
|
| Pneumonia, Aspiration | 2 | 2013 | 17 | 0.150 |
Why?
|
| Vimentin | 1 | 2018 | 18 | 0.150 |
Why?
|
| Integrin alpha Chains | 1 | 2018 | 11 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 205 | 0.150 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2018 | 1 | 0.150 |
Why?
|
| Diet Surveys | 4 | 2021 | 43 | 0.150 |
Why?
|
| Cadherins | 1 | 2018 | 80 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 67 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 123 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 377 | 0.140 |
Why?
|
| Respiratory Tract Fistula | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 49 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 1609 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 3 | 2023 | 90 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 196 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2017 | 43 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 13 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 94 | 0.140 |
Why?
|
| Biomarkers | 6 | 2016 | 1391 | 0.140 |
Why?
|
| Paraffin Embedding | 3 | 2019 | 17 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 767 | 0.130 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 83 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 297 | 0.130 |
Why?
|
| DNA, Neoplasm | 2 | 2007 | 57 | 0.130 |
Why?
|
| Vitamin D | 1 | 2018 | 140 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 51 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2018 | 287 | 0.130 |
Why?
|
| Microcirculation | 2 | 2009 | 52 | 0.130 |
Why?
|
| Endoscopy | 1 | 2017 | 110 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2015 | 659 | 0.120 |
Why?
|
| Xanthophylls | 1 | 2015 | 23 | 0.120 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 157 | 0.120 |
Why?
|
| Leisure Activities | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 57 | 0.120 |
Why?
|
| Cell Movement | 4 | 2020 | 451 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 193 | 0.120 |
Why?
|
| Health Status Indicators | 4 | 2004 | 93 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 197 | 0.120 |
Why?
|
| RNA Stability | 2 | 2013 | 102 | 0.120 |
Why?
|
| Radiography | 2 | 2009 | 546 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2022 | 103 | 0.110 |
Why?
|
| Oral Surgical Procedures | 1 | 2014 | 2 | 0.110 |
Why?
|
| Enteral Nutrition | 4 | 2008 | 54 | 0.110 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 1 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 8 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 1647 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 36 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2013 | 9 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.100 |
Why?
|
| Human papillomavirus 6 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 231 | 0.100 |
Why?
|
| Spasm | 1 | 2013 | 10 | 0.100 |
Why?
|
| Neck Muscles | 1 | 2013 | 10 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 422 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 29 | 0.100 |
Why?
|
| Mandibular Diseases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 185 | 0.100 |
Why?
|
| Free Tissue Flaps | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mandible | 1 | 2012 | 9 | 0.100 |
Why?
|
| Osteoradionecrosis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Young Adult | 7 | 2019 | 4669 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 374 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 60 | 0.100 |
Why?
|
| Quinazolines | 1 | 2012 | 22 | 0.100 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2009 | 13 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 196 | 0.100 |
Why?
|
| Algorithms | 2 | 2016 | 999 | 0.100 |
Why?
|
| Wound Healing | 3 | 2017 | 187 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 71 | 0.090 |
Why?
|
| Facial Nerve | 2 | 2019 | 16 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2012 | 32 | 0.090 |
Why?
|
| Area Under Curve | 3 | 2019 | 146 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 92 | 0.090 |
Why?
|
| Micronutrients | 1 | 2011 | 21 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 185 | 0.090 |
Why?
|
| Gluconates | 1 | 2011 | 4 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2010 | 52 | 0.090 |
Why?
|
| Comorbidity | 5 | 2016 | 1117 | 0.090 |
Why?
|
| Forecasting | 2 | 2021 | 232 | 0.090 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 69 | 0.090 |
Why?
|
| Cetuximab | 2 | 2021 | 8 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 774 | 0.090 |
Why?
|
| Cell Division | 2 | 2010 | 447 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2010 | 13 | 0.090 |
Why?
|
| Side-Population Cells | 1 | 2010 | 3 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 17 | 0.090 |
Why?
|
| Overweight | 1 | 2012 | 249 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2011 | 166 | 0.080 |
Why?
|
| Incidence | 3 | 2017 | 1369 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1143 | 0.080 |
Why?
|
| Immunity | 2 | 2021 | 106 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 2562 | 0.080 |
Why?
|
| Hypopharynx | 1 | 2009 | 3 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2009 | 14 | 0.080 |
Why?
|
| Oropharynx | 1 | 2009 | 12 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 25 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 96 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 731 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 67 | 0.080 |
Why?
|
| Sex Factors | 2 | 2016 | 971 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2010 | 69 | 0.080 |
Why?
|
| Cartilage | 1 | 2009 | 35 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 260 | 0.080 |
Why?
|
| Larynx, Artificial | 1 | 2009 | 4 | 0.080 |
Why?
|
| Genistein | 1 | 2009 | 10 | 0.080 |
Why?
|
| United States | 5 | 2021 | 7782 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 139 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 239 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 776 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2009 | 84 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2011 | 562 | 0.070 |
Why?
|
| NF-kappa B | 2 | 2009 | 468 | 0.070 |
Why?
|
| Indoles | 1 | 2009 | 110 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 290 | 0.070 |
Why?
|
| Logistic Models | 4 | 2017 | 1270 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 189 | 0.070 |
Why?
|
| Carotenoids | 2 | 2020 | 68 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 610 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 538 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 292 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2013 | 886 | 0.070 |
Why?
|
| Biopsy, Needle | 3 | 2013 | 135 | 0.070 |
Why?
|
| Cell Separation | 3 | 2015 | 147 | 0.070 |
Why?
|
| Transcriptome | 2 | 2022 | 387 | 0.070 |
Why?
|
| Vaccination | 1 | 2010 | 362 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 458 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2017 | 865 | 0.070 |
Why?
|
| Thyroglossal Cyst | 1 | 2007 | 3 | 0.070 |
Why?
|
| Coccidioidomycosis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2008 | 123 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2013 | 859 | 0.070 |
Why?
|
| Prevalence | 3 | 2016 | 1371 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 206 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1177 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2009 | 337 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 933 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 515 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 9 | 0.060 |
Why?
|
| Sensory Receptor Cells | 1 | 2025 | 19 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2013 | 451 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2021 | 2092 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1538 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1117 | 0.060 |
Why?
|
| Ethanol | 1 | 2008 | 317 | 0.060 |
Why?
|
| Alcoholism | 1 | 2008 | 317 | 0.060 |
Why?
|
| Creatinine | 1 | 2005 | 136 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 384 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2021 | 3014 | 0.060 |
Why?
|
| Adolescent | 3 | 2014 | 6219 | 0.060 |
Why?
|
| Obesity | 1 | 2012 | 1223 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2013 | 212 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 6 | 0.060 |
Why?
|
| Speech | 2 | 2020 | 62 | 0.060 |
Why?
|
| Sick Role | 1 | 2004 | 17 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 41 | 0.050 |
Why?
|
| Pectoralis Muscles | 1 | 2004 | 8 | 0.050 |
Why?
|
| Chondrosarcoma | 1 | 2003 | 7 | 0.050 |
Why?
|
| Energy Intake | 2 | 2019 | 169 | 0.050 |
Why?
|
| Gastrostomy | 3 | 2012 | 29 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 70 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2014 | 216 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 449 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 87 | 0.050 |
Why?
|
| Swine, Miniature | 1 | 2003 | 8 | 0.050 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 34 | 0.050 |
Why?
|
| Age Factors | 3 | 2016 | 1549 | 0.050 |
Why?
|
| Weight Loss | 1 | 2005 | 271 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2003 | 39 | 0.050 |
Why?
|
| Muscles | 1 | 2004 | 178 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 21 | 0.050 |
Why?
|
| Dura Mater | 1 | 2003 | 33 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2004 | 216 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2015 | 182 | 0.050 |
Why?
|
| Apoptosis | 4 | 2013 | 1069 | 0.050 |
Why?
|
| Keratins | 1 | 2022 | 30 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2013 | 54 | 0.050 |
Why?
|
| Spinal Nerves | 1 | 2002 | 5 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2003 | 132 | 0.050 |
Why?
|
| Factor VIII | 1 | 2002 | 32 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 20 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 637 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2002 | 61 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 517 | 0.050 |
Why?
|
| Alcohol Drinking | 3 | 2013 | 314 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2025 | 1271 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2017 | 137 | 0.050 |
Why?
|
| Netherlands | 1 | 2021 | 23 | 0.050 |
Why?
|
| CpG Islands | 2 | 2013 | 216 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2021 | 27 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 148 | 0.040 |
Why?
|
| DNA End-Joining Repair | 1 | 2021 | 23 | 0.040 |
Why?
|
| Observer Variation | 2 | 2013 | 212 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 175 | 0.040 |
Why?
|
| Career Choice | 1 | 2002 | 131 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 121 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 200 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2017 | 191 | 0.040 |
Why?
|
| Time Factors | 3 | 2017 | 3752 | 0.040 |
Why?
|
| Bacteria | 1 | 2023 | 303 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 178 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 1161 | 0.040 |
Why?
|
| Carcinogens | 1 | 2020 | 37 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 84 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 20 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 68 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 169 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2666 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 268 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 60 | 0.040 |
Why?
|
| Mouth Mucosa | 2 | 2012 | 23 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 46 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 76 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2010 | 524 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2012 | 43 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 392 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 357 | 0.040 |
Why?
|
| Mutagens | 1 | 2018 | 19 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 10 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2015 | 386 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 24 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 174 | 0.040 |
Why?
|
| Fistula | 2 | 2009 | 13 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2140 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 193 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 112 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 35 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cell Survival | 2 | 2010 | 566 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2015 | 385 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 606 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 110 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2018 | 176 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 118 | 0.030 |
Why?
|
| Eating | 1 | 2018 | 138 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 854 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1004 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 153 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 289 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2018 | 187 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 312 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 765 | 0.030 |
Why?
|
| DCC Receptor | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cyclin A1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Neck | 1 | 2016 | 46 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 619 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 251 | 0.030 |
Why?
|
| Nanostructures | 1 | 2018 | 178 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 257 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 112 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 225 | 0.030 |
Why?
|
| Quercetin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 410 | 0.030 |
Why?
|
| Sleep | 2 | 2009 | 223 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 161 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 140 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 198 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 158 | 0.030 |
Why?
|
| Income | 1 | 2016 | 167 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 182 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2154 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2167 | 0.030 |
Why?
|
| Contraindications | 1 | 2014 | 52 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 359 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3366 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 286 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 87 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Exercise | 2 | 2013 | 939 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 41 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2013 | 4 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 84 | 0.030 |
Why?
|
| Child | 2 | 2014 | 4502 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2013 | 37 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 77 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 2 | 0.030 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2013 | 3 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 44 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 58 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 264 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 295 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 416 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 668 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 126 | 0.020 |
Why?
|
| Speech Disorders | 1 | 2012 | 17 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 107 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2012 | 19 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 404 | 0.020 |
Why?
|
| Functional Food | 1 | 2012 | 36 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 64 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 278 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 94 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2014 | 276 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 137 | 0.020 |
Why?
|
| Vitamin A | 1 | 2012 | 27 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 289 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 334 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 203 | 0.020 |
Why?
|
| Bromhexine | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 262 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 486 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 72 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 567 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 200 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 164 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 81 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 964 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 1322 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 164 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 160 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 232 | 0.020 |
Why?
|
| Speech, Alaryngeal | 1 | 2009 | 3 | 0.020 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 9 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 664 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 39 | 0.020 |
Why?
|
| Depression | 2 | 2008 | 890 | 0.020 |
Why?
|
| Punctures | 1 | 2009 | 64 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 979 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 115 | 0.020 |
Why?
|
| Marital Status | 1 | 2008 | 45 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 7 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 23 | 0.020 |
Why?
|
| Hyoid Bone | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mucositis | 1 | 2007 | 7 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 88 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1980 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1530 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 129 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 918 | 0.020 |
Why?
|
| Patient Admission | 1 | 2008 | 194 | 0.020 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2006 | 21 | 0.020 |
Why?
|
| Stomatitis | 1 | 2005 | 7 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 375 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2008 | 406 | 0.010 |
Why?
|
| Motor Activity | 1 | 2008 | 344 | 0.010 |
Why?
|
| Tracheotomy | 1 | 2004 | 7 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 607 | 0.010 |
Why?
|
| DNA | 1 | 2009 | 829 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 46 | 0.010 |
Why?
|
| Laryngeal Cartilages | 1 | 2003 | 3 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 370 | 0.010 |
Why?
|
| Dioxanes | 1 | 2003 | 5 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 441 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 339 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 108 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 130 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 78 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 692 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 199 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 72 | 0.010 |
Why?
|
| Polylysine | 1 | 2003 | 49 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 123 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 48 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 139 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 373 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 97 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 806 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 831 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 319 | 0.010 |
Why?
|
| Insulin | 1 | 2003 | 683 | 0.010 |
Why?
|